Ensign Peak Advisors
BBOT

Ensign Peak Advisors’s BridgeBio Oncology BBOT Stock Holding History

Ensign Peak Advisors’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.87M Buy
+320,874
New +$3.45M 0.01% 642

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ensign Peak Advisors's BBOT Position: Q1 2026 in Review

Ensign Peak Advisors opened a new position in BridgeBio Oncology (BBOT) in Q1 2026: 320,874 shares worth $2.87M. The stake represents 0.01% of the portfolio and ranks #642 among its holdings.

67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • Ensign Peak Advisors held 320,874 shares of BridgeBio Oncology worth $2.87M as of Q1 2026.
  • BridgeBio Oncology was a new Ensign Peak Advisors position in Q1 2026.
  • BridgeBio Oncology made up 0.01% of Ensign Peak Advisors's portfolio in Q1 2026, its #642 holding.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.